Skip to main content

Alnylam Pharmaceuticals Value Stock - Dividend - Research Selection

Alnylam Pharmaceuticals

ISIN: US02043Q1076, WKN: A0CBCK

Market price date: 02.06.2021
Market price: 142,85 USD




Alnylam Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 24-02-2021
Cash flow
Net operating cash flow -614.961.000
Capital Expenditures -70.361.000
Free cash flow -685.321.984
Balance sheet
Total Equity 1.016.250.000
Liabilities & Shareholders equity 3.407.060.000
Income statement
Net income -858.281.000
Eps (diluted) -7,460
Diluted shares outstanding 116.427.000
Net sales/revenue 492.853.000

Fundamental ratios calculated on: 02-06-2021

Ratios
Key figures 02-06-2021
Cash flow
P/C -27,05
   
P/FC -24,27
Balance sheet
ROI-25,19
ROE29,83
Income statement
P/E-19,15
Div. Yield0,00%
P/B16,37
P/S33,75


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolALNY
Market Capitalization16.631.597.056,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.alnylam.com


Description of the company

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.alnylam.com